4D Molecular pauses enrollment in Fabry trials after kidney problems in three patients
4D Molecular Therapeutics said it has stopped enrolling patients in its two clinical trials of a gene therapy being investigated for Fabry disease.
The biotech will wait until the second half to evaluate 12-month clinical data on the six patients enrolled on 4D-310. The two trials, one in the US and the other in Taiwan and Australia, were each estimated to enroll 18 adults with the disease, in which the body lacks the enzymes needed to break down fats. For those with the inherited lipid storage disorder, fats build up in blood vessels and tissue, which leads to difficulties in the kidneys, heart and nervous system.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.